

Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

Information Governance Department

Suite 9

Buckingham Row

Brick Kiln Lane

Wigan

WN1 1XX

Email: foi@wwl.nhs.uk

Web: www.wwl.nhs.uk

Ref: FOI/2023/8625

Date Received: 18th January 2023

Response Due: 15th February 2023

Date: 8th March 2023

Dear Sir/Madam

You asked:

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following three questions:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

	Acute Trust Issue	Homecare	Outsourced (Leigh Infirmary)	Total
Adalimumab - Humira	0	16	0	16
Adalimumab Biosimilar	0	6	0	6
Apremilast	0	0	<5	<5
Bimekizumab	0	13	0	13
Brodalumab	0	0	0	0
Certolizumab	0	4	0	4
Dimethyl fumarate	<5	0	5	6
Etanercept - Enbrel	0	<5	0	<5
Etanercept Biosimilar	0	0	0	0
Guselkumab	0	49	0	49
Infliximab - Remicade	0	0	0	0
Infliximab Biosimilar	0	0	0	0
Ixekizumab	0	<5	0	<5
Risankizumab	0	25	0	25

Secukinumab	0	16	0	16
Tildrakizumab	0	0	0	0
Ustekinumab	0	24	0	24

Refusal Notice: Sec 40(2) Personal Information

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and

Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA)

Q2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:

We only record indication data for homecare patients – as such the figures below are the number of homecare patients only that meet these criteria.

	Homecare
Adalimumab - Humira	0
Adalimumab Biosimilar	0
Infliximab - Remicade	0
Infliximab Biosimilar	0
Secukinumab	0
Ustekinumab	0

Q3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

We only record indication data for homecare patients – as such the figures below are the number of homecare patients only that meet these criteria.

	Homecare
Ciclosporin	0
Methotrexate - any form and strength	0
Methotrexate injections 15mg and above	0

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 28 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wroughtington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111